Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

Christopher J. Sweeney*, Andrew J. Martin, Martin R. Stockler, Stephen Begbie, Leanna Cheung, Kim N. Chi, Simon Chowdhury, Mark Frydenberg, Lisa G. Horvath, Anthony M. Joshua, Nicola J. Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A. North, Francis Parnis, Wendy Parulekar, David Pook, Neil ReaumeShahneen K. Sandhu, Alvin Tan, Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott G. Williams, Diana Winter, Sonia Yip, Alison Y. Zhang, Robert Zielinski, Ian D. Davis, ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

47 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences